Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/04/2021 | 02:15pm EST

Y-mAbs Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 8.97 million. Net loss was USD 28.86 million compared to USD 32.83 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.82 a year ago. For the nine months, revenue was USD 25.3 million. Net loss was USD 18.38 million compared to USD 99.4 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 2.49 a year ago.


© S&P Capital IQ 2021
All news about Y-MABS THERAPEUTICS, INC.
01/25INSIDER SELL : Y-mabs Therapeutics
MT
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 66,7 M - -
Net income 2021 -49,0 M - -
Net cash 2021 85,0 M - -
P/E ratio 2021 -7,92x
Yield 2021 -
Capitalization 380 M 380 M -
EV / Sales 2021 4,42x
EV / Sales 2022 0,37x
Nbr of Employees 125
Free-Float 83,8%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,70 $
Average target price 43,40 $
Spread / Average Target 399%
EPS Revisions
Managers and Directors
Claus Juan Møller-San Pedro Director, Chief Executive & Commercial Officer
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-46.33%380
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325